Quick Answer
Gain Therapeutics, Inc. reported Revenue (ASC 606) of $55.2 thousand for fiscal year 2023.
Gain Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $55.2K | -58.4% |
| 2022 | $132.6K | -1.0% |
| 2021 | $133.9K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $55.2K | +47.0% | -42.0% |
| June 30, 2022 | $95.1K | +16.5% | +153.3% |
| March 31, 2022 | $37.5K | — | +135.0% |
| September 30, 2021 | $16.0K | — | -80.4% |
| June 30, 2021 | $81.6K | — | — |
- Gain Therapeutics, Inc. showed a decrease of -58.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2021–2023 period, Gain Therapeutics, Inc.’s revenue (asc 606) has declined by 58.8% (from $133.9 thousand to $55.2 thousand).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: